Quantcast
Last updated on April 17, 2014 at 10:07 EDT

Latest Antiretroviral drug Stories

2014-02-04 11:29:24

Nearly half of HIV-infected teenagers and young adults forego timely treatment, delaying care until their disease has advanced, which puts them at risk for dangerous infections and long-term complications, according to a study led by the Johns Hopkins Children's Center. The researchers say their findings, published Feb. 3 in JAMA Pediatrics, are particularly troubling in light of mounting evidence that starting treatment as early as possible can go long way toward keeping the virus in...

2014-01-31 00:21:48

PITTSBURGH and MUMBAI, India, Jan. 31, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its India-based subsidiary Mylan Pharmaceuticals Private Limited has been named Gilead Sciences, Inc.'s (Nasdaq: GILD) exclusive branded medicines business partner for India. Under the agreement, Mylan will market and distribute in India Gilead's: -- HIV therapies Viread(® )(tenofovir disoproxil fumarate), Truvada(®) (emtricitabine/tenofovir disoproxil fumarate) and the...

2014-01-28 12:20:14

Drugs used to treat HIV penetrate poorly into lymphatic tissues where most HIV replication takes place and there is persistent low-level virus replication in these tissues according to research from the University of Minnesota and University of Nebraska Medical Center. The results appear in the latest issue of the Proceedings of the National Academy of Sciences (PNAS). "We know the drugs we use today are effective because our patients are doing better and living longer, but these drugs...

Researchers Demonstrate 'Guided Missile' Strategy To Kill Hidden HIV
2014-01-10 13:59:06

University of North Carolina Health Care The finding provides a new route to killing persistent HIV-infected cells -- a major roadblock to a cure Researchers at the UNC School of Medicine have deployed a potential new weapon against HIV – a combination therapy that targets HIV-infected cells that standard therapies cannot kill. Using mouse models that have immune systems composed of human cells, researchers led by J. Victor Garcia, PhD, found that an antibody combined with a...

2014-01-10 08:24:14

The funding marks the collaborative backing for a cocktail approach to fighting the HIV virus and critically for combating resistance by targeting treatment on an individual basis NEW YORK, Jan. 10, 2014 /PRNewswire/ -- The New York science philanthropist, Jeffrey Epstein, has put his support behind the celebrated Elton John AIDS Foundation (EJAF) to combat HIV resistance to drugs. For more than a decade, scientists have applied a cocktail of inhibitors and other drugs to suppress...

2014-01-09 11:36:55

Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have identified that injection frequency and taking anti-retroviral therapy for HIV are risk factors for nonfatal drug overdoses among Russians who are HIV positive and inject drugs. Alexander Walley, MD, MSc, an attending physician in general internal medicine at BMC and an assistant professor of medicine at BUSM, is the study's lead author. Published in the journal AIDS Care, the study was done...

2014-01-09 08:27:16

PITTSBURGH, Jan. 9, 2014 /PRNewswire/ -- Mylan, Inc. (Nasdaq: MYL) today announced that Zyomyx's MyT4(TM) point-of-care CD4 diagnostic test has received the CE Certificate of Conformity in the European Union, an important step toward launching this innovative test and expanding access to affordable, accessible and reliable diagnostics for people living with HIV globally. As a result, the MyT4(TM) CD4 test can now bear the CE Mark, which demonstrates that the MyT4(TM) CD4 test complies...

2013-12-23 08:27:14

The Brazilian Government is Heavily Investing in the Local Manufacturing of ARVs, Hindering Market Entry of New Drugs, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 23, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Brazil's National Health System (SUS) currently provides coverage for 22 drugs that are distributed free of charge to more than 300,000...

Scientists Discover How Immune Cells Die During HIV Infection And Identify Potential Drug To Block AIDS
2013-12-20 13:04:27

Gladstone Institutes Research led by scientists at the Gladstone Institutes has identified the precise chain of molecular events in the human body that drives the death of most of the immune system's CD4 T cells as an HIV infection leads to AIDS. Further, they have identified an existing anti-inflammatory drug that in laboratory tests blocks the death of these cells—and now are planning a Phase 2 clinical trial to determine if this drug or a similar drug can prevent HIV-infected people...

2013-12-19 11:42:36

Life expectancy of treated HIV-positive individuals approaches that of general population A 20-year-old HIV-positive adult on antiretroviral therapy (ART) in the U.S. or Canada may be expected to live into their early 70's, a life expectancy approaching that of the general population, according to results published December 18, 2013, in the open access journal PLOS ONE by Hasina Samji and colleagues from the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) and the North American...


Latest Antiretroviral drug Reference Libraries

0_a4499f7c8759b5cbe79bad5eca319070
2011-01-26 14:08:59

Human immunodeficiency virus (HIV), a lentivirus, causes acquired immunodeficiency syndrome (AIDS) which is a condition in humans were the immune system begins to fail, leading to life-threatening opportunistic infections. Infection is transferred through bodily fluids where HIV is present as both free virus particles and within infected immune cells. The four most common routes of infection are unsafe sex, contaminated needles, breast milk, and transmission from an infected mother to her...

More Articles (1 articles) »